Nova Eye Medical Limited
Research Nova Eye Medical Limited (EYE.AX) on Bullrun: market cap AUD 37.04M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEYE.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryMedical Devices
- CurrencyAUD
- Market capAUD 37.04M
- Financial periodFY2026
Valuation Snapshot
latest market cap is AUD 37.04M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | n/a | n/a | n/a | -0.02 | n/a | n/a | n/a |
| FY2025 | AUD 29.27M | -AUD 9.06M | -AUD 6.58M | 68.6% | -0.04 | AUD 5.06M | AUD 3.02M | AUD 18.97M |
| FY2024 | AUD 23.33M | -AUD 8.79M | -AUD 8.31M | 86.6% | -0.04 | AUD 6.15M | AUD 3.35M | AUD 21.33M |
| FY2023 | AUD 17.03M | -AUD 15.29M | -AUD 7.62M | 84.5% | -0.1 | AUD 7.42M | AUD 1.53M | AUD 23.19M |
| FY2022 | AUD 13.63M | -AUD 7.50M | -AUD 10.31M | 83.2% | n/a | AUD 8.00M | AUD 1.94M | AUD 30.40M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 37.04M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Nova Eye Medical Limited
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nova Eye Medical Limited's market cap?
Nova Eye Medical Limited's market capitalization is AUD 37.04M.
What does Nova Eye Medical Limited do?
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease.